BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Immunomedics, Inc. 

300 American Road

Morris Plains  New Jersey  07950-2450  U.S.A.
Phone: 201-605-8200 Fax: 973-605-8282


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
Immunomedics, Inc. (IMMU) Presents Clinical Data On Novel Antibody-Drug Conjugates For Solid Cancer Therapy 11/21/2014 11:51:27 AM
Immunomedics, Inc. (IMMU) Announces Orphan Drug Designation For Veltuzumab For The Treatment Of Pemphigus 11/21/2014 11:44:10 AM
Immunomedics, Inc. (IMMU) Presents Clinical Data On Novel Antibody-Drug Conjugates For Solid Cancer Therapy 11/20/2014 2:25:23 PM
Immunomedics, Inc. (IMMU) Announces Six Presentations On Epratuzumab In Lupus At Leading Rheumatology Meeting 11/14/2014 8:37:31 AM
Immunomedics, Inc. (IMMU) Receives Third Edison Patent Award From Research & Development Council Of New Jersey 11/7/2014 7:50:42 AM
Immunomedics, Inc. (IMMU) Announces First Quarter Fiscal 2015 Results And Clinical Program Developments 11/6/2014 7:59:59 AM
Immunomedics, Inc. (IMMU) Provides Update On Phase 2 Study Of Isactuzumab Govitecan In Patients With Diverse Metastatic Solid Cancers 10/30/2014 7:22:15 AM
Immunomedics, Inc. (IMMU) To Present Updated Clinical Results With Solid-Tumor Antibody-Drug Conjugates At Upcoming Conferences 10/22/2014 7:24:15 AM
Immunomedics, Inc. (IMMU) Announces European Orphan Drug Designation For Isactuzumab Govitecan For Pancreatic Cancer Treatment 10/20/2014 7:22:29 AM
Immunomedics, Inc. (IMMU) Announces Presentations At The 2014 European Association Of Nuclear Medicine Congress 10/13/2014 8:10:06 AM
12345678910...